Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040
Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property protection in the world's largest pharmaceutical market. This allowance fortifies Cardiol's global intellectual property portfolio, adding to granted and pending patent applications in Europe, Japan, Canada, Australia, and
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2025-11-13 7:45 AM EST | Cardiol Therapeutics Inc.
Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Ontario and Chicago, Illinois--(Newsfile Corp. - November 12, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's second fiscal quarter ended September 30, 2025 (the company's fiscal Q2 2026). All dollar amounts in this press release are in United States dollars unless specified otherwise. Key business update Medexus is currently focused on delivering strong p
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-12 6:06 PM EST | Medexus Pharmaceuticals Inc.
Restart Life Sciences Announces Private Placement Financing
Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce a non-brokered private placement of up to 10,000,000 units in the capital of the Company (each, a "Unit") at a price of CAD $0.10 per Unit for aggregate gross proceeds of up to CAD $1,000,000 (the "Offering"). Each Unit purchased will include one common share and one transferable common share p
Technology, Biotechnology, Health
2025-11-12 4:22 PM EST | Restart Life Sciences Corp.
Adia Med Files Provisional Patent for Breakthrough Regenerative Medical Protocol
Winter Park, Florida--(Newsfile Corp. - November 12, 2025) - ADIA Nutrition, Inc. (OTCQB: ADIA), a leader in advanced regenerative health solutions, today announced the filing of a provisional patent application with the United States Patent and Trademark Office (USPTO) for a novel medical protocol designed to enhance regenerative outcomes. This Patent Pending innovation represents a significant advancement in ADIA's mission to deliver cutting-edge, science-backed therapies. The proprie
Healthcare and Hospitals, Health
2025-11-12 9:15 AM EST | Adia Nutrition Inc.
BioHarvest Sciences to Attend the Craig-Hallum 16th Annual Alpha Select Conference on November 18, 2025
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 12, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to attend the Craig-Hallum 16th Annual Alpha Select Conference taking place on Tuesday, November 18th, 2025 in New York, NY.
Biotechnology, Pharmaceuticals, Health
2025-11-12 8:42 AM EST | BioHarvest Sciences Inc.
Izotropic Launches Podcast Episode #2: AI and the Future of Breast Imaging: How Izotropic is Leading the Innovation
Sacramento, California--(Newsfile Corp. - November 12, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the release of the second episode in its podcast series:
2025-11-12 8:00 AM EST | Izotropic Corporation
Rock Salt Marketing Appoints Spencer Bierman as New SEO Director
Salt Lake City, Utah--(Newsfile Corp. - November 12, 2025) - Award-winning Utah- and Tennessee-based digital marketing agency Rock Salt Marketing has announced the appointment of Spencer Bierman as its new SEO Director.
Real Estate, Travel, Health, Legal
2025-11-12 7:30 AM EST | Rock Salt Marketing Cooperative
Elite Pharmaceuticals Receives FDA Approval for Generic Requip XL(R)
Northvale, New Jersey--(Newsfile Corp. - November 12, 2025) - Elite Pharmaceuticals, Inc. (OTCBB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a generic version of Requip XL® (Ropinirole Extended-Release Tablets USP), with strengths of 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg tablets. Ropi
Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-12 7:00 AM EST | Elite Pharmaceuticals, Inc.
Red Light Holland's Wholly Owned Subsidiary Happy Caps Expands Safeway Partnership to 123 Stores Across the U.S. Pacific Northwest, in Time for American Thanksgiving
Toronto, Ontario--(Newsfile Corp. - November 11, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), a company engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, is pleased to announce a major U.S. retail expansion milestone for its wholly owned subsidiary, 4316747 Nova Scotia Limited o/a Happy Caps Mushroom Farm ("Happy Caps") with Albertso
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2025-11-11 8:39 AM EST | Red Light Holland Corp.
Cosmo's ESG Rating Upgraded by S&P Global; Strengthens Supplier Sustainability Oversight Engagement, and Italian Manufacturing Plant Awarded EcoVadis Bronze Medal
Dublin, Ireland--(Newsfile Corp. - November 11, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced two major milestones in its sustainability journey, underscoring its commitment to transparency, responsible operations, and ESG leadership. Cosmo’s 2025 S&P Global Corporate Sustainability Assessment has been upgraded to the 67th percentile, a significant improvement from la
Healthcare and Hospitals, Health
2025-11-11 1:01 AM EST | Cosmo Pharmaceuticals N.V.
CardioComm Receives TSX Venture Exchange Approval for Announced Loan Facility
Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, is pleased to announce that it has received approval from the TSX Venture Exchange for its November 3, 2025 announced loan agreement dated November 3, 2025 (the "Loan Agreement") representing aggregate funding of $512,000. The
Technology, Healthcare and Hospitals, Health
2025-11-10 11:37 PM EST | CardioComm Solutions, Inc.
LevelJump Announces 2025 Third Quarter Results
Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company") is pleased to announce its financial results for the three months and nine months ended September 30, 2025. Financial and Operational Highlights Revenues were $4.84 million in the third quarter compared to $4.45 million in the same period the prior year, an increase of 8.7%. For the nine months ended S
Healthcare and Hospitals, Health
2025-11-10 10:31 PM EST | LevelJump Healthcare Corp.
BioHarvest Sciences Announces Closing of $19.9 Million Upsized Public Offering of Common Stock and Exercise of Underwriter's Option to Purchase Additional Shares
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 10, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, announces the closing of its previously announced underwritten public offering of 2,846,854 shares of common stock, no par value, and at a public offering price of $7.00 per share, which includes 361,854 shares issued upon the exercise by the
Biotechnology, Pharmaceuticals, Health
2025-11-10 4:18 PM EST | BioHarvest Sciences Inc.
Game-Changing Alliance: Adia Labs and Axia
Winter Park, Florida--(Newsfile Corp. - November 10, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and premium wellness solutions, today announced a strategic partnership between its research and development division, Adia Labs, and AxiaMD, a premier provider of nationwide physician oversight and compliance services for med spas, IV clinics, physician assistants, nurse practitioners, and wellness practices. Under the agreement, AxiaMD's extensive network
Healthcare and Hospitals, Health
2025-11-10 9:00 AM EST | Adia Nutrition Inc.
Functional Brands Inc. and Market Performance Group Forge High-Impact Partnership to Supercharge Growth of Kirkman(R) Brand in the Expanding Health & Wellness Market
Lake Oswego, Oregon--(Newsfile Corp. - November 10, 2025) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and performance products, is thrilled to announce a new commercial partnership with Market Performance Group (MPG), a top-tier omnichannel commerce agency known for driving exponential growth for leading consumer brands. This strategic collaboration marks an exciting new chapter for the Kirkman® brand-one of the most trusted names in nutritional supplem
Household / Consumer / Cosmetics, Health
2025-11-10 8:00 AM EST | Functional Brands Inc.
Delivra Health Brands Reports Financial Results for First Quarter of Fiscal 2026 Highlighting Continued Growth of Dream Water (R) and LivRelief(TM)
Growth of Dream Water® US and Canada by 8% compared to same quarter last year Growth of Dream Water® E-commerce by 74% compared to same quarter last year Growth of LivRelief™ by 9% compared to same quarter last year Growth of LivRelief™ E-commerce by 16% compared to same quarter last year Vancouver, British Co
Cannabis, Health, Cannabis Extractor, Cannabis Manufacturer
2025-11-10 7:25 AM EST | Delivra Health Brands Inc.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025
Northvale, New Jersey--(Newsfile Corp. - November 10, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2026 fiscal year will be released on Friday, November 14, 2025. Elite's management will host a live conference call on Monday, November 17th, at 11:30 AM EST to discuss the company's financial and operating re
Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-10 7:00 AM EST | Elite Pharmaceuticals, Inc.
LevelJump Announces Receipt of Notice of Requisition for a Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - November 7, 2025) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company") announces that a notice of requisition of a meeting of shareholders (the "Requisition") was delivered to the registered office of the Company on November 3, 2025. The Requisition has been made by Frank Teti and Franmar Properties Ltd. (collectively the "Concerned Shareholders") which requires that the Company call and hold a meeting of shareholders pursuant to s
Healthcare and Hospitals, Health
2025-11-07 5:00 PM EST | LevelJump Healthcare Corp.
Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it will present clinical data from its ongoing Phase 1b clinical trial at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in National Harbor, Ma
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-07 10:30 AM EST | Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program
King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio announced today that its INTASYL compound PH-762 is the winner of the 2025 Immunomodulatory Solution of the Year award. This is the fifth annual BioTech Breakthrough Awards program conducted by
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-07 7:45 AM EST | Phio Pharmaceuticals Corp.